Rigid amphipathic fusion inhibitors (RAFIs) are lipophilic inverted-cone-shaped molecules thought to antagonize the membrane curvature transitions that occur during virus-cell fusion and are broad-spectrum antivirals against enveloped viruses (Broad-SAVE). Here, we show that RAFIs act like membrane-binding photosensitizers: their antiviral effect is dependent on light and the generation of singlet oxygen ( 1 O 2 ), similar to the mechanistic paradigm established for LJ001, a chemically unrelated class of Broad-SAVE. Photosensitization of viral membranes is a common mechanism that underlies these Broad-SAVE.
R
ecently, a few broad-spectrum antivirals have been described that target enveloped virus entry (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Antivirals that can target the biophysical process of virus-cell membrane fusion itself, rather than any particular viral protein, not only have the potential to be truly broad spectrum (against any enveloped virus) but also will likely have a high barrier to resistance (11) (12) (13) (14) . Thus, gaining a fuller mechanistic understanding of antiviral compounds reported to target the virus-cell membrane fusion process is essential for developing the potential of this exciting broadspectrum antiviral strategy.
We originally described a class of thiazolidine-based lipophilic broad-spectrum antivirals against enveloped viruses (Broad-SAVE) (e.g., LJ001) that target a late stage of virus-cell fusion at the level of membrane merger (9) . Follow-up studies indicated that LJ001, our first generation of Broad-SAVE, and the oxazolidine-based JL series of compounds, our second generation Broad-SAVE, act as membrane-targeted photosensitizers: they generate singlet oxygen ( 1 O 2 ) in the plane of the membrane, and 1 O 2 -mediated lipid oxidation results in changes in the biophysical properties of the viral envelope that are not conducive to virus-cell membrane fusion (8) . The salient point is that at antiviral concentrations, 1 O 2 -mediated lipid oxidation is not detrimental to metabolically active cell membranes. This is the key mechanistic paradigm that has never been explicitly stated and tested (15) until our recent studies (8, 9) .
Shortly after our original description of the membrane-targeted broad-spectrum antiviral LJ001 (9), St. Vincent et al. de-1 O 2 production in 3 mM POPC (a C9 monounsaturated model phospholipid) LUV. It should be noted that concentrations indicated in POPC are the local concentration of dUY11 in the strict lipid bilayer volume, calculated as described in reference 25. , where K sv * is the apparent Stern-Volmer constant (indicating the reduction of fluorescence by the conversion of DMA to DMAO 2 ), V is the sphere-of-action volume (i.e., the sphere that surrounds the chromophore within which the "quencher" can be considered to be in contact with the chromophore), and N A is Avogadro's constant. Mean Ϯ SD, n ϭ 3 independent measurements. scribed another class of antiviral molecules termed rigid amphipathic fusion inhibitors (RAFIs) that also inhibit a number of enveloped viruses at the level of virus-cell fusion (6) . Mechanistic studies indicate that RAFIs have "remarkably similar properties" to LJ001. However, the authors present evidence that these RAFIs inhibit virus-cell fusion by stabilizing the positive curvature of membranes by virtue of their molecular geometry: RAFIs are inverted-cone-shaped molecules with a large hydrophilic head group attached to a rigid and planar hydrophobic moiety that inserts into the membrane. Thus, RAFIs are thought to act like similarly shaped lysophospholipids, which are known to impair the critical positive-to-negative membrane transitions that occur during virus-cell fusion (2, 7) . Nevertheless, we noted that the rigid and planar hydrophobic moiety present in all effective RAFIs is a perylene group (Fig. 1A) (3, 6) , which is a well-known fluorescent lipid probe and photosensitizer (16) (17) (18) .
We, and others, have previously questioned whether the nanomolar potency and apparent irreversible antiviral activity of RAFIs can be attributed entirely to their molecular geometry (11, 13) . Thus, we synthesized the exemplar RAFI compound, dUY11 (see the supplemental material and Fig. 1A ), and asked if dUY11 is a photosensitizer and, if so, whether its ability to generate 1 O 2 does contribute to its antiviral activity (13) .
Indeed, dUY11 generated 1 O 2 in solution, as indicated by the oxidation of the 1 O 2 -specific trap 9,10-dimethylanthracene (DMA) (8) (Fig. 1B) . Anaerobic conditions (argon [Ar]) or addition of an antioxidant (␣-tocopherol) abrogated dUY11-induced DMA oxidation, underscoring the specificity of these results. DMA is lipophilic and highly fluorescent when intercalated into membranes. DMA fluorescence quenching analysis upon oxidation by dUY11 in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) large unilamellar vesicles (LUV) further confirmed the ability of dUY11 to generate 1 O 2 in membranes ( Fig.  1C) and established dUY11 as a type II photosensitizer (19) .
Next, to determine if the photosensitizing properties of dUY11 contributed to its antiviral activity, we performed dose-response experiments in the presence or absence of light, as previously described (8) . Human herpes simplex virus 1 (HSV-1), a virus extensively used to characterize the antiviral activity of RAFIs, was preincubated with various concentrations of dUY11 for 30 min in the absence of light and then either exposed to a white-light source for an additional 10 min or not, before being used to infect Vero cells. Infectivity analysis confirmed that dUY11 was as potent against HSV-1 (0.2 nM 50% inhibitory concentration [IC 50 ]) ( Fig. 2A ) and as nontoxic (1.5 mM 50% cytotoxic concentration [CC 50 ]) (data not shown) as previously reported (3, 6) . However, dUY11 showed a complete absence of antiviral activity when no light was provided ( Fig. 2A) , even at concentrations 100-fold above the reported IC 50 for dUY11 (3, 6) . Similar results were obtained using various enveloped RNA viruses unrelated to HSV-1 (a DNA virus), such as Newcastle disease virus (NDV), Sendai virus (SeV), and vesicular stomatitis virus (VSV) (Fig. 2B) , confirming that the broad-spectrum antiviral activity of dUY11 against enveloped viruses is indeed light dependent. As a type II photosensitizer, dUY11's antiviral activity should be dependent on both its concentration and the time of light exposure. Indeed, using NDV-green fluorescent protein (GFP), we found that the antiviral activity of dUY11 increased (lower IC 50 ) as a function of the time of light exposure (Fig. 2C) , similar to what has been described for LJ001 (8) .
Finally, sodium azide (NaN 3 ), a specific quencher of 1 O 2 (20) , reversed the antiviral activity of dUY11 against HSV-1 and NDV (Fig. 3A and B, respectively) . Note that the apparent potency of dUY11 against both viruses was greater in experiment 2 (lower IC 50 ), concordant with the lesser degree of NaN 3 -mediated reversal observed, especially at higher concentrations (75 nM) of dUY11. In sum, our results confirm the specific involvement of 1 O 2 in dUY11's broad-spectrum antiviral activity.
1 O 2 -mediated lipid oxidation targets the CϭC double bonds in unsaturated phospholipids and introduces polar hydroxylated acyl chains in the middle of the hydrophobic membrane lipid bilayer. Clustering of these oxidized phospholipids results in decreased membrane fluidity, which negatively impacts on the membrane's ability to undergo the extreme membrane curvature transitions occurring during virus-cell fusion (8, 21) . Thus, photosensitization of viral membranes requires the presence of unsaturated acyl chains and results in a decrease in membrane fluidity or increased rigidity. To determine if dUY11 induced such biophysical changes in model membranes, we measured the fluorescence anisotropy of the 1,6-diphenyl-1,3,5-hexatriene (DPH) probe after treatment of artificial membranes with dUY11. In Fig. 4A , the dose-dependent increase in anisotropy (⌬ϽrϾ DPH ), mediated by dUY11, reflected its effect on increasing membrane rigidity (22) . Furthermore, the anisotropy increase was more prominent in unsaturated (POPC) than saturated (dimyristoylphosphatidylcholine [DMPC]) phospholipid LUV (Fig. 4A) , consistent with the specific targeting of unsaturated phospholipids by dUY11-induced 1 O 2 . The latter was confirmed by the addition of the 1 O 2 quencher NaN 3 , which brought the anisotropy levels of dUY11-treated POPC LUV back to the background levels observed with DMPC LUV (Fig. 4B) .
Thus, we propose a mechanism of action for the exemplar RAFI, dUY11, that is similar to the membrane-targeting photosensitizers previously described as Broad-SAVE, such as LJ001 (9) (26, 27) , the latter being similar to the plasma membranes of mammalian cells. For any given membrane rigidity (blue, green, and red lines), note the exponential increase in absolute energy required (k B T/nm 2 ) for bending membranes as the vesicle diameter gets smaller. The inset shows a specific simulation where a 5% increase in membrane rigidity (50¡55 k B T) on a 100-nm-sized vesicle (virion) results in at least a 3-log increase in energy required to reach the estimated diameter of the fusion stalk (10 nm). The actual energy cost is likely much higher, as the model assumes bending from an initially flat membrane, whereas fusion requires bending from a positively curved to a negatively curved membrane. and its oxazolidine counterparts (e.g., JL103, JL118, and JL122) (8) . Our model is consistent with all published data on RAFIs, including those regarding membrane fluidity and lipid-phase transitions of model membranes (3, 6) . In contrast, the purely geometric mechanism proposed by Schang and colleagues (stabilization of positive curvature) (3, 6) cannot explain the light dependency of dUY11's antiviral activity or the reversal of its antiviral activity by the 1 O 2 quencher NaN 3 . dUY11 (RAFIs) could very well stabilize positive membrane curvature at high molar concentrations; however, this effect is unlikely to contribute to the antiviral effect seen at its nanomolar IC 50 .
Recently, Stachowiak and colleagues provided a lucid accounting of the energetics involved in membrane curvature (21) . The energy cost per membrane area of creating a curved sphere was estimated as G bending ϭ (8)/(4r 2 ), where is the bending rigidity of the membrane and r is the vesicle radius. The bending rigidity ranges from 10 k B T for a highly fluid membrane with unsaturated phospholipids to 50 k B T for plasma (or plasma-like) membranes containing 50% cholesterol, where k B is the Boltzmann's constant and T the absolute temperature. The bending energetics model suggests that even a small increase in bending rigidity, when coupled to a large decrease in vesicle radius (such as the diameter of the fusion stalk during hemifusion), can result in an exponentially insurmountable amount of energy required to bend the membranes for productive fusion to occur (Fig. 4C) .
In conclusion, since all the active RAFIs described to date (3, 6) possess a perylene core, it is likely that their antiviral activity is effectuated through the photosensitizing mechanism of action proposed for dUY11 (13) . Our data underscore the generalizability and relevance of our recently proposed mechanism of action for Broad-SAVE that target the lipid component of membrane fusion (8) . Although the clinical potential of photoactivated membrane-targeting Broad-SAVE appears limited by photophysical hurdles, structure-activity relationship (SAR) studies that leverage advances in photochemistry and nanotechnology may overcome these hurdles (23, 24) . The unique mechanism of action of these Broad-SAVE warrants further investigation.
